Partner Headlines - GSK

  1. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  2. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  3. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  4. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  5. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  6. Glaxo more bullish than Q1

    IBD
  7. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  8. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  9. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  10. GlaxoSmithKline

    IBD
  11. Novartis EPS beats the Street

    IBD
  12. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  13. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  14. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  15. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  16. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  17. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  18. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  19. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  20. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  21. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  22. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  23. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  24. Benzinga's Weekend M&A Chatter

    Benzinga
  25. Gilead Sciences Still has More Upside

    GuruFocus
  26. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  27. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  28. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  29. Isis Pharma To Develop GI Drugs With J&J

    IBD
  30. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  31. Ebola Drug Work Continues

    IBD
  32. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
  33. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  34. Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR

    GuruFocus
  35. Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines

    Benzinga
  36. Pfizer Spreading Its Wings Into A New Domain Of Life Sciences

    GuruFocus
  37. Merck Bets $9.5 Billion On Cubist's War On Superbugs

    IBD
  38. GlaxoSmithKline's Move A Testament That Pharma Companies Are ...

    Benzinga
  39. The Top 5 European Stocks Held During Q3

    GuruFocus
  40. BioMarin buying Prosensa

    IBD
  41. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  42. Screening Pharma Stocks Amid Turnaround

    YCharts
  43. Jeff Auxier Buys Berkshire Hathaway in Third Quarter

    GuruFocus
  44. Apollo may make Glaxo offer

    IBD
  45. Irving Kahn Starts New Position In GlaxoSmithKline

    GuruFocus
  46. Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014

    GuruFocus
  47. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  48. Kahn Brothers' Third Quarter Numbers

    GuruFocus
  49. Ebola Vaccine Contenders

    Benzinga
  50. Stock Futures Upshift On Data; Yahoo, Broadcom, Boeing Climb

    IBD
  51. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  52. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  53. Sarepta Therapeutics Shares Up On Ebola Drug Safety Study

    Benzinga
  54. Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear

    IBD
  55. Ebola-Related Pharma Stocks Soar On First U.S. Case

    IBD
  56. Action Heats Up in Ebola-Related Equities

    FoxBusiness
  57. Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF

    GuruFocus
  58. Pharma Stocks: Surprising Shift In U.S. Drug Market

    YCharts
  59. Royal Bank of Scotland

    IBD
  60. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  61. International Securities For A Diversified Income Portfolio

    GuruFocus
  62. Could European Funds Offer An Opportunity Now?

    Benzinga
  63. Widely Held Guru Stocks Trading In Europe

    GuruFocus
  64. 3 Partnerships Pushing The Pharmaceutical Sector Forward

    Benzinga
  65. Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB

    GuruFocus
  66. China Fines Glaxo For Bribes

    IBD
  67. Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF

    GuruFocus
  68. Stock Futures Down, But Not Far; Alibaba Sets IPO Price Range

    IBD
  69. Benzinga's M&A Chatter for Wednesday August 27, 2014

    Benzinga
  70. GSK Receives FDA Approval Of An Additional Promacta (eltrombopag) ...

    Benzinga
  71. InterMune Stock Spikes On Rare Big Biotech Buyout

    IBD
  72. 3 Dividend Kings From The U.K. I Love To Buy

    GuruFocus
  73. UPDATE: GlaxoSmithKline Receives FDA Approval For Arnuity Ellipta ...

    Benzinga
  74. Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG

    GuruFocus
  75. Intermune up on buyout buzz

    IBD
  76. You Should Consider Adding GlaxoSmithKline Based on Tremendous ...

    GuruFocus
  77. Drugmaker AstraZeneca Returns To Growth

    IBD
  78. Widely Held Guru Stocks Near 52-Week Lows

    GuruFocus
  79. Pfizer To Buy Baxter's Vaccines For $635 Million: The Positives ...

    Benzinga
  80. Glaxo, Sanofi Trend Up On Potential Deal For Established Brands

    Benzinga
  81. Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS

    GuruFocus
  82. Glaxo, Genmab Report Positive Interim Result for Phase III Study ...

    Benzinga
  83. A Look at the Week's Top Dividend Growers

    GuruFocus
  84. Markets Little Changed Ahead Of The Federal Reserve's Policy ...

    Benzinga
  85. GlaxoSmithKline

    IBD
  86. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  87. Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine ...

    Benzinga
  88. Morning Market Movers

    Benzinga
  89. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  90. Highest Yielding Stocks Widely Held By The Gurus

    GuruFocus
  91. British Stocks: Sweet Spot For European Value

    YCharts
  92. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  93. ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart ...

    Benzinga
  94. Advances In HIV, Hep C Treatments Could Spark Renewed Interest ...

    Benzinga
  95. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  96. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  97. Major British Companies Lead Top Guru-Held UK and Ireland Stocks ...

    GuruFocus
  98. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  99. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica ...

    Benzinga
  100. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga
Trading Center